Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of “Hold” by Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS) has been given a consensus recommendation of “Hold” by the ten analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $22.2857.

A number of research firms have recently weighed in on KROS. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Keros Therapeutics in a report on Monday, December 29th. Wells Fargo & Company cut their target price on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 11th. Oppenheimer reaffirmed an “outperform” rating and set a $27.00 target price (up previously from $23.00) on shares of Keros Therapeutics in a research note on Wednesday, November 12th. Zacks Research downgraded shares of Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Finally, Bank of America raised their price objective on Keros Therapeutics from $18.00 to $19.00 and gave the company a “neutral” rating in a report on Friday, November 28th.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $18.77 on Thursday. Keros Therapeutics has a 1 year low of $9.12 and a 1 year high of $22.55. The stock has a market capitalization of $571.92 million, a price-to-earnings ratio of 12.19 and a beta of 0.89. The company’s 50 day simple moving average is $19.43 and its 200 day simple moving average is $16.68.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.93. Keros Therapeutics had a return on equity of 9.51% and a net margin of 26.12%.The firm had revenue of $14.26 million during the quarter, compared to analysts’ expectations of $4.22 million. During the same period in the prior year, the company earned ($1.41) earnings per share. The company’s quarterly revenue was up 3585.6% on a year-over-year basis. As a group, analysts anticipate that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KROS. Tower Research Capital LLC TRC boosted its position in Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after buying an additional 1,888 shares during the period. Farther Finance Advisors LLC bought a new position in shares of Keros Therapeutics during the third quarter valued at $47,000. CWM LLC raised its stake in shares of Keros Therapeutics by 87.5% during the second quarter. CWM LLC now owns 5,000 shares of the company’s stock valued at $67,000 after acquiring an additional 2,333 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Keros Therapeutics during the third quarter worth $103,000. Finally, Police & Firemen s Retirement System of New Jersey grew its stake in shares of Keros Therapeutics by 29.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company’s stock worth $110,000 after purchasing an additional 1,892 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.